From next year, a large number of drugs will be unable to get health insurance!

"Pharmaceutical network industry dynamics" medical insurance drug catalog adjustment has been China's pharmaceutical industry attention to the event.
, the 2020 national medical insurance drug catalog adjustment work has been officially started.
this year is the second year that the health-care directory has been normalized.
that this time will still take into account the functional positioning of basic medical insurance, clinical needs of drugs, fund affordability.
this round of adjustment will bring out a batch of drugs, thus making room for more clinically valuable drugs to enter the catalog.
the drug catalog adjustment is expected to be completed by the end of the year, with the aim of landing in 2021.
, which drugs will be transferred out? It is understood that after comprehensive consideration is assessed that the risk is greater than the benefits of drugs, catalog of "zombie drugs", the international general de-market drugs, can be replaced by high prices but the negotiations have not been successful single drugs will be transferred out of the catalog.
From the Interim Measures for the Administration of Essential Medical Insurance Drugs, which was officially implemented by the State Health Insurance Administration on September 1, Article 8 stipulates that eight categories of drugs, such as drugs and health care drugs, which mainly play a tonic role, shall not be included in the medical insurance catalogue.
9 of the Measures stipulates that if the following conditions exist, the medical insurance catalogue shall be transferred directly.
In particular, these include: drugs that have been revoked, revoked or cancelled by the drug regulatory authorities, drugs that have been placed on the negative list by the relevant departments, drugs that have been assessed to be more risky than benefits, and other five cases, taking into account such factors as clinical value, adverse reactions and drug economy.
article 10 of the Measures stipulates that medical insurance catalogues may be called out if the price or cost is significantly higher and there is no reasonable reason for the same treatment;
addition, Article 36 of the Measures clearly stipulates that, in principle, the Drug Catalog will not add OTC drugs.
of medical insurance drugs is closely related to people's medical treatment and medical insurance reimbursement.
the "Measures" clearly 8 categories of drug health insurance will no longer be paid for the news has also caused people's heated discussion.
, for example, for "preventive vaccines are not included in basic health insurance" situation, many netizens are guessing whether future vaccinations need to be self-costed? In fact, preventive vaccines are defined as relative to "therapeutic vaccines", known as hepatitis B vaccines, HPV vaccines, white vaccines, measles vaccines, influenza vaccines, etc. are preventive vaccines.
in preventive vaccines, it is divided into immunization programme vaccines (free of charge) and non-immunization programme vaccines (at your own expense).
, according to the Notice on the Implementation of the Expanded National Immunization Programme, the cost of immunization programme vaccines is paid directly by the State finance and not from the Health Insurance Fund.
that is, preventive vaccines have never been included in our list of health insurance drugs.
industry veterans said that the development of the national basic health insurance directory, generally need to give priority to the selection of clinically necessary, accurate efficacy and affordable drugs.
from the Measures, it is not difficult to see that the economics of drugs will become one of the important value dimensions of the medical insurance drug transfer catalog.
With the adjustment of the list of medical insurance drugs, the "moisture" of the relevant drug prices will gradually be squeezed out, and the drug price will be reduced accordingly, which is conducive to further reducing the burden of the patient's drug price and meeting the patient's drug demand.